Key PointsQuestion
Do women and men with a high bleeding risk have different long-term outcomes after percutaneous coronary intervention?
Findings
In this prespecified secondary analysis of patients with a high bleeding risk in the LEADERS FREE trial, women and men had a similar 2-year incidence of the primary composite safety (cardiac death, myocardial infarction, or stent thrombosis) and efficacy (target lesion revascularization) end points. Women, compared with men, experienced greater overall major bleeding within the first 30 days and greater major bleeding from vascular access sites.
Meaning
The findings suggest that women with a high bleeding risk should not be denied the benefits of percutaneous coronary intervention when indicated and that bleeding avoidance strategies should be uniformly adopted for all patients, with particular attention to women.
Importance
Female sex has been identified as a risk factor for bleeding after percutaneous coronary intervention (PCI) and may have contributed to the underuse of drug-eluting stents in women. This risk may be further enhanced among patients with a high bleeding risk.
Objective
To assess the 2-year outcomes by sex in patients with a high bleeding risk who were enrolled in the LEADERS FREE trial.
Design, Setting, and Participants
This cohort study is a prespecified, sex-based secondary analysis of the LEADERS FREE double-blind, randomized clinical trial that was conducted at 68 sites in 20 countries from December 2012 to May 2014. Patients with a high bleeding risk who underwent PCI and met the trial eligibility criteria were enrolled at the participating sites and followed up for up to 2 years.
Interventions
Patients were randomized 1:1 to either a bare-metal stent or a polymer-free, biolimus A9-eluting drug-coated stent with 1-month of dual antiplatelet therapy.
Main Outcomes and Measures
The primary safety end point was a composite of cardiac death, myocardial infarction, or stent thrombosis. The primary efficacy end point was clinically driven target lesion revascularization. Bleeding was assessed using the Bleeding Academic Research Consortium (BARC) scale, and the source of bleeding was recorded.
Results
A total of 2432 patients with a high bleeding risk were included in the study. Of these patients, the mean (SD) age was 75 (9) years, and 1694 (69.7%) were men and 738 (30.3%) were women. Women and men had similar incidence of the 2-year primary safety (14.7% vs 13.6%; P = .37) and efficacy (9.2% vs 9.5%; P = .70) end points. The drug-coated stent was found to be superior to the bare-metal stent in both sexes, with lower target lesion revascularization (women: 6.3% vs 12.1%; men: 7.0% vs 12.0%; P for interaction = .70) and similar rates of the primary safety end point (women: 12.4% vs 17.0%; men: 12.6% vs 14.5%; P for interaction = .40). Overall, 2-year BARC types 3 to 5 major bleeding (10.2% vs 8.6%; P = .14) was not statistically different between the sexes, but women experienced greater BARC types 3 to 5 major bleeding within the first 30 days (5.1% vs 2.4%; P = .007) and greater vascular access site major bleeding than men (2.2% vs 0.5%; P < .001). In both sexes, vascular (women: hazard ratio [HR], 3.45 [95% CI, 1.51-7.87]; men: HR, 4.14 [95% CI, 1.33-12.95]) and nonvascular major bleeding (women: HR, 3.76 [95% CI, 2.17- 6.53]; men: HR, 4.62 [95% CI, 3.23-6.61]) were associated with greater 2-year mortality.
Conclusions and Relevance
This study found no sex differences in the ischemic outcomes of patients with a high bleeding risk after PCI, but women appeared to demonstrate greater early bleeding and major bleeding from the vascular access site. Both women and men with major bleeding seemed to experience worse 2-year mortality, suggesting that bleeding avoidance strategies should be uniformly adopted for all patients, with close attention dedicated to women to avoid denying them the benefits of PCI.
Trial Registration
ClinicalTrials.gov Identifier: NCT02843633
Compared with men, women typically present with a higher risk of adverse outcomes after percutaneous coronary intervention (PCI) attributed to advanced age and greater comorbidities.1-3 In particular, women are at high risk for bleeding events after PCI1,2 and, consequently, may be undertreated with PCI4 or may be preferentially treated with a bare-metal stent (BMS) rather than a drug-eluting stent (DES),5 although BMS use is declining. Studies have shown that women are less likely to receive dual antiplatelet therapy (DAPT),6 potent antiplatelet therapy,1,3 or other secondary prevention medications.7 For women, these risk-treatment biases may result in not only being denied the benefits of DES PCI5 but also having higher subsequent hospitalization rates with angina.8 Compared with BMS, DES substantially reduces the risk of target lesion revascularization (TLR), but new-generation, polymer-free drug-coated stents (DCS) have been designed to accelerate healing and to mitigate the risk of stent thrombosis (ST) attributed to polymer hypersensitivity with durable polymer DES.9-11 The LEADERS FREE trial was the first randomized clinical trial (RCT) to demonstrate the long-term efficacy and safety of a biolimus A9-eluting DCS (BioFreedom; Biosensors International) compared with a BMS with 1 month of DAPT in patients with a high bleeding risk.12-14
In this prespecified secondary analysis of data from the LEADERS FREE trial, we (1) examined the baseline and trial inclusion characteristics of the enrolled patients with a high bleeding risk by sex; (2) compared the 2-year clinical end points by sex and then assessed for interaction between sex and stent type; (3) explored the differences in vascular access site and nonvascular bleeding by sex as well as by radial or femoral PCI approaches; and (4) evaluated the effect of bleeding on mortality by sex.
The LEADERS FREE trial was a double-blind randomized clinical trial conducted at 68 sites in 20 countries from December 2012 to May 2014.12 The protocol (Supplement 1) was developed by the executive committee, and the institutional review board at each of the 68 sites approved the study. All patients provided written informed consent. The study was conducted by Centre Européen de Recherche Cardiovasculaire, an independent research organization in Massy, France, and was sponsored by Biosensors Europe (based in Morges, Switzerland).
In this cohort study, which is a prespecified secondary analysis of data from the LEADERS FREE trial, eligible patients with coronary artery disease and an indication for PCI met 1 or more of the inclusion criteria established to define a population of patients who had increased bleeding risk or who were considered by the LEADERS FREE investigators to be candidates for a BMS instead of a DES because of their perceived need for short, 1-month DAPT. The main eligibility criteria were individuals aged 75 years or older who had a need for chronic oral anticoagulation, kidney failure, a need for a surgical intervention within 12 months of the PCI, anemia or recent blood transfusion, or a diagnosis of non–skin cancer during the past 3 years.
Study Procedures and Follow-up
Patients were randomized 1:1 to undergo PCI with either the biolimus A9-eluting DCS or a similar BMS (Gazelle; Biosensors Interventional Technologies). Randomization was performed in blocks of 16 using either a web-based system or a telephone interactive voice-response system (both from Merge Healthcare). The patients, investigators, and members of the clinical events committee and the executive committee were blinded to group assignments. All target lesions were treated with at least 1 study stent. Staged procedures were allowed within 1 week after the index procedure, and all stents used were assigned (DCS or BMS type).
According to the study protocol, all patients received both aspirin and a P2Y12 inhibitor, preferably clopidogrel, for 30 days, followed by a single antiplatelet agent, preferably aspirin. Patients who were discharged while taking a vitamin K antagonist received either triple therapy or the vitamin K antagonist plus clopidogrel during the first 30 days of discharge.
Follow-up visits were conducted at 30 days, when the change from DAPT to single antiplatelet therapy was prescribed, and at 360 days. Further follow-up by telephone or clinic visit took place at 60, 120, and 720 days.
End Points and Definitions
The primary safety end point was a composite of cardiac death, myocardial infarction (MI), or ST. The primary efficacy end point was clinically driven TLR. Myocardial infarction was adjudicated according to the third universal definition of MI.15 All other ischemic end point events were adjudicated according to the Academic Research Consortium definitions.16,17 All ischemic and bleeding events were adjudicated by an independent clinical events committee. Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definitions,17 and the site of bleeding was recorded by the clinical events committee. Major bleeding was defined as BARC types 3 to 5, and major or minor bleeding was deemed as BARC types 2 to 5. BARC types 2 to 5 are any actionable bleeding events requiring prompt evaluation by a health professional with or without an increased level of care, whereas BARC types 3 to 5 are major bleeding events requiring some intervention and typically combinations of transfusion, vasoactive drugs, or a surgical procedure. The bleeding events adjudications form is shown in eFigure 1 in Supplement 2. The present analysis reports 2-year outcomes by sex.
Patients were compared by sex. Categorical data were presented as number (%) and were compared using the χ2 test. Continuous data, presented as mean (SD), were compared using the parametric, unpaired, 2-tailed t test. Outcomes were analyzed in a time-to-event manner using the Kaplan-Meier methods and compared using the log-rank test. Hazard ratios (HRs) and 95% CIs for outcomes were calculated using Cox proportional hazards regression models. Multivariable adjustment was conducted to estimate the risk of clinical outcomes in women and men (with men as the reference group) according to imbalances in baseline characteristics. The following variables were included in the model: current smoking status, hypertension, diabetes, previous MI, previous PCI, previous coronary artery bypass graft, peripheral vascular disease, renal insufficiency, chronic obstructive pulmonary disease, multivessel disease, angina status, lesion length, and reference vessel diameter. Interaction testing was performed for outcomes by sex and stent type.
To calculate the HR for death after a major bleeding event, we divided the follow-up of each patient into time in follow-up before and after a major bleeding using the methods previously described.14 The association between major bleeding and subsequent mortality was analyzed with a Cox proportional hazards regression model using a time-updated categorical variable that enters the model on the day of the event. The calculated HR, therefore, was a comparison of the hazard of death after a major bleeding event to the hazard of death before an event (including the hazard in patients who did not have an event during follow-up).
All data were analyzed using SAS, version 9.4 (SAS Institute Inc). Two-sided P < .05 was considered statistically significant. Data analysis was conducted from August 2017 to October 2019.
The study population included 2432 patients with a high bleeding risk. Of these patients, the mean (SD) age was 75 (9) years, and 1694 (69.7%) were men and 738 (30.3%) were women. Table 1 shows the baseline patient-, procedure- and lesion-level characteristics by sex. Women compared with men were older (mean [SD] age, 78 [8] years vs 75 [9] years; P < .001) with a higher prevalence of acute coronary syndrome but a lower prevalence of previous MI or previous PCI and current smoking status. With respect to eligibility criteria (Figure 1), more women than men were 75 years or older (76.7% vs 58.9%; P < .001) and had a higher prevalence of chronic kidney failure (creatinine clearance, <40 mL/min in 24.1% vs 16.9%; P < .001) or hemoglobin level less than 11 g/L (17.8% vs 14.6%; P = .05). Men more often than women had an indication for oral anticoagulation (37.8% vs 32.4%; P = .01), planned major surgery within the next 12 months (17.8% vs. 13.1%, P = .005), expected DAPT nonadherence within 1 year for major surgical procedures (4.1% vs 2.4%; P = .04), a history of hospital admission within the previous 12 months for bleeding (3.7% vs 2.2%; P = .05), or higher prevalence of malignant neoplasm (11.0% vs 7.0%; P = .002). According to angiographic data, fewer women than men had multivessel disease, and women had less severe site-reported stenoses. Compared with men, women had shorter mean lesion length, and more women had small vessel disease. Fewer women than men underwent radial PCI. The baseline patient and procedural characteristics by sex and stent type are shown in eTable 1 in Supplement 2.
At discharge, the rate of DAPT use was similar in women and men (96.0% vs 97.0%; P = .18). At 37 days, a higher proportion of women than men continued receiving DAPT (11.6% vs 8.6%; P = .02). However, at 12 months (8.8% vs 8.6%; P = .87) and 24 months (5.4% vs 6.9%; P = .20), no differences in the proportion of women vs men receiving DAPT were observed.
Table 2 presents the 2-year incidence and adjusted risk of clinical outcomes by sex. At the 2-year follow-up, women with a high bleeding risk compared with their male counterparts had a similar incidence of the primary safety end point (14.7% vs 13.6%; P = .37) (adjusted HR, 1.00; 95% CI, 0.78-1.28; P = .98) and efficacy end point (9.2% vs 9.5%; P = .70) (adjusted HR, 0.95; 95% CI, 0.70-1.31; P = .77) (Figure 2) as well as similar rates of MI (7.2% vs 7.2%; P = .95) and ST (2.5% vs 2.1%; P = .47). After adjustment for baseline differences, the outcomes remained similar by sex.
The 2-year clinical outcomes by stent type and sex are shown in eTable 2 in Supplement 2. Outcomes (expressed as Kaplan Meier %) were better in women and men with lower TLR in those patients who received a DCS as opposed to a BMS (women: 6.3% vs 12.1%; men: 7.0% vs 12.0%; P for interaction = .70), and a similar incidence of the primary safety end point was found in both sexes (women: 12.4% vs 17.0%; men: 12.6% vs 14.5%; P for interaction = .40) (eFigure 2 in Supplement 2). No differences in the incidence of ST were observed between the DCS and BMS in women or in men (women: 1.7% vs 3.3%; men: 2.3% vs 1.8%; P for interaction = .13).
With respect to bleeding outcomes, no statistically significant differences were seen in the incidence of overall 2-year major BARC types 3 to 5 bleeding by sex (10.2% in women vs 8.6% in men; P = .14) (adjusted HR, 1.25; 95% CI, 0.92-1.69; P = .16) (Figure 2) or by stent type (women: 9.8%with DCS vs 10.6% with BMS, P = .71; men: 8.6% with DCS vs 8.5% with BMS, P = .84; P for interaction = .64) (eFigure 2 in Supplement 2). However, women compared with men experienced statistically significant greater rates of major bleeding between 0 and 30 days (5.1% vs 2.4%; P = .007) (adjusted HR, 2.22; 95% CI, 1.38-3.62; P = .001) and 0 and 60 days (5.9% vs 2.9%; P < .001) (adjusted HR, 2.22; 95% CI, 1.42-3.47; P < .001) after the PCI. Furthermore, women experienced higher rates of major and major or minor bleeding from the vascular access site compared with men (BARC types 3-5: 2.2% in women vs 0.5% in men [P < .001]; BARC types 2-5: 5.6% in women vs 2.0% in men [P < .001]) (Figure 3; eTable 3 in Supplement 2). Men compared with women had greater rates of nonvascular major or minor bleeding (BARC types 2-5: 16.4% vs 12.8%; P = .03), mainly genitourinary bleeding (BARC types 2-5: 3.1% vs 0.3%; P < .001). The rates of gastrointestinal bleeding were similar in women and men (BARC types 2-5: 6.9% vs 6.3%; P = .49) (BARC types 3-5: 5.2% vs 4.2%; P = .25). In a comparison of PCI access route, radial (vs femoral) access was associated with 2- to 3-fold lower bleeding event rates from the vascular access site in both sexes (BARC types 2-5 women: 3.0% vs 8.8%; P < .001; men: 1.0% vs 3.5%; P < .001) without interaction (P for interaction = .72) (Figure 3, eTable 4 in Supplement 2).
In both sexes, vascular (women: HR, 3.45 [95% CI, 1.51-7.87]; men: HR, 4.14 [95% CI, 1.33-12.95]) and nonvascular (women: HR, 3.76 [95% CI, 2.17- 6.53]; men: HR, 4.62 [95% CI, 3.23-6.61]) major bleeding events were associated with greater 2-year mortality. The associations between vascular and nonvascular major bleeding and 2-year mortality in women and men are shown in eTable 5 in Supplement 2.
The main findings of the present prespecified secondary analysis were as follows. First, women and men enrolled in the LEADERS FREE trial were deemed to be at high bleeding risk for considerably different reasons. Second, compared with men, women had a lower prevalence of previous MI or revascularization and smoking but presented more often with acute coronary syndrome. Procedurally, women had shorter lesion lengths, more small vessel disease, less multivessel disease, and less severe stenoses. They underwent radial PCI less often than men. Third, at the 2-year follow-up, women and men had similar incidence of the primary safety and efficacy end points as well as MI and ST. With respect to stent type, both women and men had lower risk of TLR with the DCS compared with the BMS along with similar incidence of the primary safety end point and ST. Fourth, although women and men had similar rates of any BARC types 3 to 5 major bleeding, women experienced a higher incidence of bleeding from the vascular access site than did men. Radial access for PCI resulted in substantially lower vascular bleeding events in both sexes without interaction. Fifth, patients who experienced vascular or nonvascular major bleeding had worse 2-year mortality.
Sex-based studies have consistently shown that women have higher crude incidences of ischemic events after PCI.1-3 This finding has been considered to be the result of the differences in baseline comorbidities rather than biological factors, especially with older age in women, higher prevalence of diabetes, renal insufficiency, and high platelet reactivity.18 Nevertheless, previous studies have suggested that women are undertreated with PCI4 and potent antiplatelet therapies1,3 and are more likely to undergo earlier DAPT cessation.19 Part of the reason for this finding may be that women demonstrate higher bleeding event rates because of greater vascular complications and some possible differences in non–access site–related bleeding.1,2
Drug-eluting stents have substantially evolved since their conception, and polymer-free DES offers the advantage of reducing the risk of TLR without increasing the ST associated with polymer hypersensitivity.9-11,20,21 Yet, physicians have typically been biased in treating patients with a high bleeding risk, avoiding DES owing to the need for longer-term DAPT. To our knowledge, the LEADERS FREE trial is the first RCT to specifically enroll a population with a high bleeding risk and to demonstrate the long-term safety and efficacy of polymer-free DCS compared with BMS with only 1 month of DAPT after PCI.12,13 These results are important given that patients with a high bleeding risk, who may represent up to one-fifth of patients who undergo PCI, constitute a special group at elevated risk of both bleeding and ischemic events.22-24 Although the most frequent eligibility criteria for enrollment in the LEADERS FREE trial were age 75 years or older and the need for anticoagulation,12 we observed considerable differences by sex in the eligibility criteria of enrolled patients. Women with a high bleeding risk were older, had more chronic kidney disease, and had hemoglobin levels less than 11 g/L, whereas men with a high bleeding risk were more likely to be on chronic oral anticoagulation; have expected DAPT cessation within 12 months of the PCI for a major surgical procedure; and have a history of bleeding or malignant neoplasm. Other baseline sex differences were aligned with those found in past PCI studies, with a lower prevalence of previous revascularization and smoking3 as well as shorter lesion length and more small vessel disease in women than in men.25
Despite these baseline differences, women and men with a high bleeding risk had similar crude outcomes at the 2-year follow-up. However, women experienced greater rates of vascular access site bleeding, whereas men suffered more nonvascular bleeding, particularly genitourinary actionable bleeding. Other studies involving patients who underwent PCI with primarily femoral access have shown women to have a substantially higher risk of bleeding.1,2 Although radial access for PCI is an important bleeding avoidance strategy, the Study of Access Site for Enhancement of PCI for Women trial did not demonstrate considerable benefits in bleeding outcomes with radial vs femoral access in women.26 Nevertheless, the practice of radial access for PCI has evolved in the past decade, allowing for increased uptake and improved operator skills. In the present trial, although radial access for PCI was performed in more than 50% of patients, more men than women underwent successful radial PCI. Radial PCI was associated with at least 3-fold lower event rates compared with femoral PCI in both sexes, whereas women who underwent radial PCI had almost similar vascular bleeding rates as men who underwent femoral PCI, emphasizing the high bleeding risk in women.
With respect to ischemic outcomes, we found that, although event rates in patients with a high bleeding risk were higher than in other comparatively unselected contemporary PCI trials,27,28 no substantial differences by sex were found. These results remained unchanged even after adjustment for baseline differences. The polymer-free DCS performed better than the BMS in both women and men. Although no interaction was noted by sex, women had a considerably lower incidence of the composite efficacy end point (clinically driven TLR) compared with men. These data suggest that patients of both sexes with a high bleeding risk benefit from DCS PCI with 1-month DAPT, thus eligible women with a high bleeding risk should not be denied the benefits of DCS technology.
To our knowledge, the LEADERS FREE trial is the first RCT to specifically compare outcomes between polymer-free DCS and BMS in patients with a high bleeding risk. However, other PCI studies have suggested low ST event rates with 1 month of DAPT after a second-generation DES PCI.29-31
This analysis has some limitations. We did not collect information on adherence to medications other than antiplatelet therapy during follow-up. Although the trial protocol recommended low-dose aspirin, we did not record data on the use of low- or high-dose aspirin. We used a broad definition of high bleeding risk, but this analysis was the first sex-based subanalysis in patients with a high bleeding risk enrolled in an RCT. Thus, it provides detailed sex-based descriptions of baseline demographic characteristics and long-term outcomes up to 2 years with a DCS or BMS PCI and 1 month of DAPT.
Women at increased risk of bleeding had similar 2-year ischemic outcomes to men, suggesting that, when indicated, women should not be denied the benefits of PCI. In both women and men at increased risk of bleeding, the polymer-free biolimus A9-eluting DCS performed better than the BMS in terms of TLR and should be favored regardless of sex. Women underwent radial access PCI less often and experienced higher incidences of vascular bleeding compared with men; however, in both sexes, vascular and nonvascular major bleeding appeared to be associated with worse 2-year mortality. Bleeding avoidance strategies during PCI should be uniformly adopted in all patients, especially women.
Accepted for Publication: December 3, 2019.
Corresponding Author: Roxana Mehran, MD, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 (roxana.mehran@mountsinai.org).
Published Online: May 20, 2020. doi:10.1001/jamacardio.2020.0285
Author Contributions: Dr Mehran had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mehran, Lang, Spaulding, Stoll.
Acquisition, analysis, or interpretation of data: Mehran, Chandrasekhar, Urban, Lang, Windhoevel, Copt, Stoll, Morice.
Drafting of the manuscript: Mehran, Chandrasekhar, Copt.
Critical revision of the manuscript for important intellectual content: Mehran, Chandrasekhar, Urban, Lang, Windhoevel, Spaulding, Stoll, Morice.
Statistical analysis: Mehran, Copt.
Obtained funding: Urban.
Administrative, technical, or material support: Mehran, Spaulding, Stoll.
Supervision: Urban, Lang.
Conflict of Interest Disclosures: Dr Mehran reported receiving grants from Eli Lilly/DSI, AstraZeneca, The Medicines Company, BMS, and OrbusNeich as well as consulting fees from Janssen Pharmaceuticals Inc, Medscape, Osprey Medical Inc, and Watermark Research Partners outside the submitted work. Dr Urban reported receiving personal fees from Biosensors and other support from Centre Européen de Recherche Cardiovasculaire (CERC) during the conduct of the study as well as other support from MedAlliance and personal fees from Edwards Lifescience outside the submitted work. Dr Lang reported receiving other support from Biosensors Europe SA during the conduct of the study and grants from Actelion and AOP Orphan Pharma outside the submitted work. Dr Windhoevel reported receiving other support from CERC during the conduct of the study. Dr Spaulding reported receiving other support from Medtronic, Zoll, Medpass, Xeltis, Stentys, and Techwald outside the submitted work as well as personal fees from Abiomed, Abbott, and AstraZeneca. Dr Copt reported receiving other support from and being an employee of Biosensors SA during the conduct of the study. Dr Stoll reported receiving other from Biosensors International during the conduct of the study and outside the submitted work. Dr Morice reported being the chief executive officer of CERC. No other disclosures were reported.
Funding/Support: This study was funded by Biosensors Europe.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The funder provided support for statistical analysis.
Group Information: LEADERS FREE group members are: Executive Committee Members: Philip Urban (Hôpital de la Tour, Geneva, Switzerland), Marie-Claude Morice (ICPS, Générale de Santé, Massy, France), Alexander Abizaid (Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil), Ian T Meredith (Monash Heart, MCRC Monash University, Melbourne, Australia), Stuart J. Pocock (London School of Hygiene and Tropical Medicine, London, UK), Didier Carrié (Toulouse Rangueil Hospital, Toulouse, France), Christoph Naber (Elisabeth Krankenhaus, Essen, Germany), Samantha Greene (Biosensors Europe, Morges, Switzerland), Hans-Peter Stoll (Biosensors Europe, Morges, Switzerland). Steering Committee Members and Regional Coordinating Investigators: Luc Bilodeau (Royal Victoria Hospital, Montreal, Canada), Mariano Valdes-Chavarri (Arrixaca University Hospital, Murcia, Spain), Alaide Chieffo (San Raffaele Hospital, Milan, Italy), Haim Danenberg (Hadassah Hebrew University Medical Center, Jerusalem, Israel), Franz Eberli (Triemli Hospital, Zürich, Switzerland), Marcel Gosselink (Isala Klinieken, Zwölle, The Netherlands), Keith Oldroyd (West of Scotland Regional Heart & Lung Centre Golden Jubilee National Hospital, Glasgow, Scotland), Robayaah Zambahari (Institute Jantung Negara, Kuala Lumpur, Malaysia). Clinical Events Committee: Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, New York, USA), Andreas Baumbach (Bristol Royal Infirmary, Bristol, UK), Stéphane Cook (University & Hospital Fribourg, Fribourg, Switzerland), Petr Kala (University Hospital Brno and Masaryk University, Brno, Czech Republic), Jacques Machecourt (CHU A. Michallon, Grenoble, France), Josefina Mauri (Hospital Universiari Germans Trials I Pujol, Barcelona, Spain), Goran Olivecrona (Skane University Hospital, Lund Sweden), Sonia Petronio (Ospedale di Cisanello, Pisa, Italy), Flavio Ribichini (University of Verona, Verona, Italy), Leif Thuesen (Aalborg University Hospital, Aalborg, Denmark). Investigators by Country and Recruiting Sites: France: Janusz Lipiecki (Pôle Santé République, Clermont-Ferraud, France). Philippe Brunel (Clinique de la Fontaine, Dijon, France), Philippe Garot (Hôpital Claude Galien ICPS, Générale de Santé, Quincy-Sous-Sénart, France), Jacques Berland (Clinique Saint Hilaire, Rouen, France), Mohamed Abdellaoui (Groupe Hospitalier Mutualiste de Grenoble (GHM), Grenoble, France), Didier Carrié, CHU Toulouse Rangueil, Toulouse), Thomas Hovasse (Hôpital Privé Jacques Cartier, Massy), Luc Maillard, (GCS ES Axium–Rambot, Aix en Provence), Christian Spaulding (European Hospital Georges Pompidou, Paris), Marc Bedossa (CHU Rennes, Rennes), Jean Fajadet (Clinique Pasteur, Toulouse), Eric Maupas (Clinique Les Franciscaines, Nîmes), Marc Eric Moulichon (Clinique Saint-Pierre, Perpignan), Eric Van Belle (Hôpital Cardiologique–CHRU de Lille, Lille). United Kingdom: Suneel Talwar (Dorset Heart Centre Royal Bournemouth Hospital, Bournemouth, UK), Ian B. A. Menown (Craigavon Cardiac Centre, Belfast), Keith Oldroyd (West of Scotland Regional Heart & Lung Centre Golden Jubilee National Hospital, Glasgow), Jonathan Byrne (Kings College Hospital, London), Simon Redwood (St Thomas’Hospital, London), Azfar Zaman (Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle), David Hildick-Smith (Sussex Cardiac Centre-Brighton and Sussex University Hospitals NHS Trust, Brighton), Mark De Belder (The James Cook University Hospital, Middlesborough), Ever Grech (South Yorkshire Cardiothoracic Center-Northern General Hospital, Sheffield), Philip Strike (Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth), Piers Clifford (Harefield Hospital, Uxbridge), Simon James Walsh (Belfast City Hospital, Belfast). Germany: Gert Richardt (Herzzentrum Segeberger Kliniken, Bad Segeberg, Germany), Philip Lurz (Universität Leipzig–Herzzentrum, Leipzig), Florian Krackhardt (Charité Campus Virchow Klinikum, Berlin), Franz-Josef Neumann (Zentrum Bad Krozingen, Freiburg), Werner Jung (Schwarzwald-Baar Klinikum, Villingen-Schwenningen), Christoph Naber (Klinik für Kardiologie und Angiologie Elisabeth-Krankenhaus, Essen). Spain: Andres Iñiguez (Complejo Hospital Meixoeiro, Vigo), Mariano Valdes-Chavarri (Arrixaca University Hospital, Murcia), Agustin Albarran (Hospital 12 de Octubre, Madrid), Raul Moreno (University Hospital La Paz, Madrid). Italy: Roberto Violini (San Camillo Forlanini, Roma), Corrado Tamburino (University of Catania-Ferrarotto Hospital, Catania), Antonio Bartorelli (University of Milan-Centro Cardiologico Monzino, Milano), Maurizio Tespili (Ospedale Bolognini, Seriate–Bergamo), Silvio Klugmann (Ospedale Niguarda Ca’ Granda, Milano), Antonio Colombo (San Raffaele Hospital, Milano). Switzerland: Franz Eberli (Triemli Hospital, Zürich), Oliver Gaemperli (University Hospital Zürich, Zürich), Eric Eeckhout (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne), Tiziano Moccetti (Cardiocentro Ticino, Lugano), Philip Urban (La Tour Hospital, Geneva). Singapore: Paul Ong (Tan Tock Seng Hospital), Lim Soo Teik (National Heart Centre Singapore) Chan Koo Hui (National University Health System). Denmark: Evald H Christiansen (Aarhus University Hospital, Skejby, Aarhus), Thomas Engström (Rigshospitalet, Copenhagen University Hospital, Copenhagen). Hong Kong: Stephen Lee (Queen Mary Hospital, Hong Kong). Malaysia: Robayaah Zambahari (Institute Jantung Negara, Kuala Lumpur). Australia: Ian Meredith (Monash Heart, Monash Medical Centre, Clayton, Victoria), Darren Walters (Prince Charles Hospital, Queensland). Thailand: Damras Tresukosol (Siriraj Hospital, Bangkok). Belgium: Stefan Verheye (ZNA Middleheim, Antwerpen), Christophe Dubois (UZ Leuven, Department of cardiovascular medicine acute and interventional cardiology, Leuven). Israel: Ran Kornowski (Rabin Medical Center, Beilinson & Hasharon Hospitals), Petah Tikva), Haim Danenberg (Hadassah Hebrew University Medical Center, Jerusalem), Shmuel Banai (Tel Aviv Medical Center, Tel Aviv). Latvia: Andrejs Erglis (Latvian Center of Cardiology Pauls Stradins Clinical University Hospital, Riga). Norway: Rune Wiseth (Trondheim University Hospital, Trondheim). The Netherlands: Marcel Gosselink (Isala Klinieken Zwolle, Zwolle). Canada: Luc Bilodeau and Sonny Dandona (Royal Victoria Hospital Centre (CUSM), Montreal). Ireland: David Foley (Beaumont Hospital, Dublin). Austria: Irene Lang (Medical University of Vienna, Department of Cardiology, Vienna).
Disclaimer: Dr Mehran is an associate editor of JAMA Cardiology, but was not involved in any of the decisions regarding review of the manuscript or its acceptance.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank all patients for their participation in the trial. We acknowledge all interventional cardiologists, catheterization laboratory staff, and research teams for their contributions. These individuals received no additional compensation, outside of their usual salary, for their contributions.
1.Hess
CN, McCoy
LA, Duggirala
HJ,
et al. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS.
J Am Heart Assoc. 2014;3(1):e000523. doi:
10.1161/JAHA.113.000523
PubMedGoogle Scholar 2.Yu
J, Mehran
R, Grinfeld
L,
et al. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.
Catheter Cardiovasc Interv. 2015;85(3):359-368. doi:
10.1002/ccd.25630
PubMedGoogle ScholarCrossref 3.Chandrasekhar
J, Baber
U, Sartori
S,
et al. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: results from the PROMETHEUS study.
Catheter Cardiovasc Interv. 2017;89(4):629-637. doi:
10.1002/ccd.26606
PubMedGoogle ScholarCrossref 5.Chieffo
A, Hoye
A, Mauri
F,
et al; WIN Group. Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative.
EuroIntervention. 2010;5(7):773-779. doi:
10.4244/EIJV5I7A130
PubMedGoogle ScholarCrossref 6.Batchelor
W, Kandzari
DE, Davis
S,
et al. Outcomes in women and minorities compared with white men 1 year after everolimus-eluting stent implantation: insights and results from the PLATINUM Diversity and PROMUS Element plus post-approval study pooled analysis.
JAMA Cardiol. 2017;2(12):1303-1313. doi:
10.1001/jamacardio.2017.3802
PubMedGoogle ScholarCrossref 7.Redfors
B, Angerås
O, Råmunddal
T,
et al. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
J Am Heart Assoc. 2015;4(7):4. doi:
10.1161/JAHA.115.001995
PubMedGoogle ScholarCrossref 10.Otsuka
F, Yahagi
K, Ladich
E,
et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography.
Circulation. 2015;131(3):322-324. doi:
10.1161/CIRCULATIONAHA.114.012658
PubMedGoogle ScholarCrossref 13.Jensen
CJ, Naber
CK, Urban
P,
et al. Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy.
EuroIntervention. 2018;13(16):1946-1949. doi:
10.4244/EIJ-D-17-00720
PubMedGoogle ScholarCrossref 15.Thygesen
K, Alpert
JS, Jaffe
AS,
et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction.
J Am Coll Cardiol. 2012;60(16):1581-1598. doi:
10.1016/j.jacc.2012.08.001
PubMedGoogle ScholarCrossref 18.Yu
J, Mehran
R, Baber
U,
et al. Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Circ Cardiovasc Interv. 2017;10(2):10. doi:
10.1161/CIRCINTERVENTIONS.116.003577
PubMedGoogle ScholarCrossref 22.Mehran
R, Pocock
S, Nikolsky
E,
et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials.
JACC Cardiovasc Interv. 2011;4(6):654-664. doi:
10.1016/j.jcin.2011.02.011
PubMedGoogle ScholarCrossref 23.Chandrasekhar
J, Mehran
R, Dangas
G,
et al. Effect of thrombotic and bleeding risk according to platelet reactivity on 2-year mortality: the ADAPT-DES study.
J Am Coll Cardiol. 2017;69(11)(suppl):1012. doi:
10.1016/S0735-1097(17)34401-7
Google Scholar 24.Sorrentino
S, Claessen
B, Mehran
R,
et al. Validation of PARIS risk scores in patients treated with everolimus-eluting stents for left main coronary artery disease: analysis from the EXCEL Trial.
J Am Coll Cardiol. 2018;72(13) (suppl): B333. doi:
10.1016/j.jacc.2018.08.2078
Google Scholar 26.Rao
SV, Hess
CN, Barham
B,
et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.
JACC Cardiovasc Interv. 2014;7(8):857-867. doi:
10.1016/j.jcin.2014.04.007
PubMedGoogle ScholarCrossref 28.von Birgelen
C, Kok
MM, van der Heijden
LC,
et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
Lancet. 2016;388(10060):2607-2617. doi:
10.1016/S0140-6736(16)31920-1
PubMedGoogle ScholarCrossref 29.Silber
S, Kirtane
AJ, Belardi
JA,
et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Eur Heart J. 2014;35(29):1949-1956. doi:
10.1093/eurheartj/ehu026
PubMedGoogle ScholarCrossref